Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04440735 · ClinicalTrials.gov registry record · Phase 1

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Kahr Medical.

Active
Registry status
Phase 1
Development phase
125
Enrollment target
7
Study locations

NCT04440735 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is active but no longer recruiting, run by Kahr Medical. The registered enrollment target is 125 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (81% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04440735, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is active but no longer recruiting, sponsored by Kahr Medical.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
125 participants
Enrollment target
7
Study locations

Study Summary

Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.

Conditions Studied

Non-Small Cell Lung Cancer Colorectal Cancer Advanced Solid Tumor

Interventions

  • BIOLOGICAL Atezolizumab
  • BIOLOGICAL DSP107

Study Locations (7)

Pennsylvania

  • SKCC-Sidney Kimmel Cancer Center Thomas Jefferson University - Philadelphia
  • UPMC Hillman Cancer Center University of Pittsburgh - Pittsburgh

California

  • Moores Cancer Center, UCSD - La Jolla

Colorado

  • University of Colorado Hospital, Anschutz Cancer Pavilion (ACP) - Aurora

Florida

  • Florida Cancer Specialists - Lake Mary

Indiana

  • Indiana University Simon Cancer Center - Indianapolis

Kansas

  • KUCC / KUMCRI University of Kansas Cancer Center - Kansas City

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2020-10-07
Est. Completion 2025-09
Phase Phase 1

Sponsor

Kahr Medical

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04440735

The ClinicalTrials.gov registry entry for NCT04440735 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (81% lower). The listed sponsor is Kahr Medical, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.

NCT04440735 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Pennsylvania, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT04440735 about?

NCT04440735 is a clinical study titled "A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors". Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non sma...

What is the current status of trial NCT04440735?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2020-10-07. Estimated completion is 2025-09.

What conditions does trial NCT04440735 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor.

What interventions are being tested in trial NCT04440735?

The interventions under investigation include: Atezolizumab (BIOLOGICAL), DSP107 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04440735?

This trial is sponsored by Kahr Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04440735 being conducted?

This trial has 7 study locations across California, Colorado, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Colorectal Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.